Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biocryst Pharma Inc (BCRX)

Biocryst Pharma Inc (BCRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,577,464
  • Shares Outstanding, K 185,584
  • Annual Sales, $ 157,170 K
  • Annual Income, $ -184,060 K
  • 60-Month Beta 2.51
  • Price/Sales 9.91
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BCRX with:

Options Overview Details

View History
  • Implied Volatility 85.64% ( +0.09%)
  • Historical Volatility 158.67%
  • IV Percentile 97%
  • IV Rank 70.74%
  • IV High 96.86% on 05/11/22
  • IV Low 58.52% on 09/27/21
  • Put/Call Vol Ratio 0.60
  • Today's Volume 1,931
  • Volume Avg (30-Day) 4,450
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 204,138
  • Open Int (30-Day) 197,415

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.36
  • Number of Estimates 6
  • High Estimate -0.20
  • Low Estimate -0.48
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.61 +16.95%
on 05/12/22
11.09 -19.75%
on 04/18/22
-2.49 (-21.83%)
since 04/14/22
3-Month
7.61 +16.95%
on 05/12/22
19.30 -53.89%
on 02/18/22
-10.24 (-53.50%)
since 02/17/22
52-Week
7.61 +16.95%
on 05/12/22
19.99 -55.48%
on 02/16/22
-5.48 (-38.11%)
since 05/17/21

Most Recent Stories

More News
BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...

BCRX : 8.90 (+4.71%)
Why BioCryst Stock Lost Nearly 4% of Its Value Today

The biotech whiffs on both revenue and profitability for its first quarter, and indicates more losses are in store.

BCRX : 8.90 (+4.71%)
BioCryst Pharmaceuticals (BCRX) Q1 2022 Earnings Call Transcript

BCRX earnings call for the period ending March 31, 2022.

BCRX : 8.90 (+4.71%)
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Lags Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of -2.56% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

BCRX : 8.90 (+4.71%)
XERS : 2.42 (+9.50%)
BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones

—Q1 2022 ORLADEYO net revenue of $49.7 million— —ORLADEYO net revenue in 2022 expected to be no less than $250 million— —Company provides update on...

BCRX : 8.90 (+4.71%)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...

BCRX : 8.90 (+4.71%)
Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

XBI : 71.46 (+4.38%)
BCRX : 8.90 (+4.71%)
ARNA : 99.99 (+0.06%)
EXEL : 20.69 (+2.12%)
IBB : 116.52 (+2.85%)
FBT : 135.51 (+2.22%)
Why BioCryst Stock Shot Nearly 5% Higher Today

The company gets a glowing green light from a foreign regulator for one of its pipeline drugs.

BCRX : 8.90 (+4.71%)
7 Top-Rated Biotech Stocks to Buy for Q2

These stocks don’t depend on typical economic cycles to thrive

MRUS : 16.28 (+1.88%)
BCRX : 8.90 (+4.71%)
MRNA : 142.28 (+4.42%)
ITOS : 19.01 (+3.88%)
BNTX : 159.80 (+5.69%)
BioCryst to Report First Quarter 2022 Financial Results on May 5

RESEARCH TRIANGLE PARK, N.C., April 21, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...

BCRX : 8.90 (+4.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential...

See More

Key Turning Points

3rd Resistance Point 9.60
2nd Resistance Point 9.30
1st Resistance Point 9.10
Last Price 8.90
1st Support Level 8.60
2nd Support Level 8.30
3rd Support Level 8.10

See More

52-Week High 19.99
Fibonacci 61.8% 15.26
Fibonacci 50% 13.80
Fibonacci 38.2% 12.34
Last Price 8.90
52-Week Low 7.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar